Antibacterial prophylaxis and treatment of the patients with febrile neutropenia during hematopoietic stem cell transplantation

Clinical and Transfusion Haematology

Volumn 43, Issue 1-2, 2007, Pages 3-14

  Mihaylov, G ^a   Vasileva, N ^a   Ganeva, P ^a  

^a NCHT   (Bulgaria)

Author keywords

Antibiotic cycling; Bacterial resistance; Hematopoietic stem cell transplantation; Neutropenic fever; Prophylaxis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CILASTATIN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; NEOMYCIN; OFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL INFECTION; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG USE; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MONOTHERAPY; MORTALITY; REVIEW; RISK REDUCTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 53349128036     PISSN: 08617880     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Amari, E. B. E. et al. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. - Clin. Infect. Dis., 33, 2001, 1859-1864.
2. Ariffin, H. et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. - Int. J. Infect. Dis., 4, 2000, 21-25.
3. Barnes, R. A. et N. Stallard. Severe infections after bone marrow transplantation. - Curr. Opin. Crit. Care, 7, 2001, 362-366.
4. Beelen, D. et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. - Blood, 93, 1999, No 10, 3267-3275.
5. Biron, P. et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. - J. Antimicrob. Chemother., 42, 1998, 511-518.
6. Blijlevens, N., J. Donnelly et B. Pauw. Empirical therapy of febrile neutropenic patients with mucositis: challenge of risk-based therapy. - Clin. Microbiol. Infect., 7, 2001, Suppl. 4, 47-52.
7. Bonadio, M. et G. Morelli. Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications. - Biomed. Pharmacother., 59, 2005, 511-516.
8. Brown, E. M. et D. Nathwani. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. - J. Antimicrob. Chemother., 55, 2005, 6-9.
9. Bucaneve, G. et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. - N. Engl. J. Med., 353, 2005, 977-987.
10. Cetinkaya, Y., P. Falk et C. G. Mayhall. Vancomycin-resistant enterococci. - Clin. Microbiol. Rev., 13, 2000, 686-707.
11. Chavers, L. S. et al. Association between antecedent intravenous antimicrobial exposure and isolation of vancomycin-resistant enterococci. - Microb. Drug Resist., 9, 2003, Suppl. 1, S69-S77.
12. Collin, B. A. et al. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. - Clin. Infect. Dis., 33, 2001, 947-953.
13. Craig, M. et al. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. - Bone Marrow Transplant., 39, 2007, 477-482.
14. Cruciani, M. et al. Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients. - J. Clin. Oncol., 21, 2003, No 22, 4127-4137.
15. Cruciani, M. et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. - Clin. Infect. Dis., 23, 1996, 795-805.
16. Del Favero, A. et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. - Clin. Infect. Dis., 33, 2001, 1295-1301.
17. Depauw, B. E. et al. Ceftazidime compared to piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. - Ann. Intern. Med., 120, 1994, 834-844.
18. Freeman, C. D. et al. Once daily dosing of aminoglycosides: review and recommendations for clinical practice. - J. Antimicrob. Chemother., 39, 1997, 677-686.
19. Frere, P. et al. Changing pattern of bacterial susceptibility to antibiotics in hematopoietic stem cell transplant recipients. - Bone Marrow Transplant., 29, 2002, 589-594.
20. Gafter-Gvili, A. et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. - Ann. Internal. Med., 142, 200, No 12, 979-995.
21. Gerding, D. N. Antimicrobial cycling: lessons learned from the aminoglycoside experience. - Infect. Control. Hosp. Epidemiol., 21, 2000, Suppl. S12-S17.
22. Gluckman, E. et al. Prophylaxis of bacterial infections after bone marrow transplantation. A randomized prospective study comparing oral broad-spectrum nonabsorbable antibiotics (vancomycin-tobramycin-colistin) to absorbable antibiotics (ofloxacin/ amoxicillin). - Chemotherapy, 37, 1991, Suppl. 1, 33-38.
23. Gomez -Martin, C. et al. Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: Results of a randomized clinical trial. - J. Clin. Oncol., 18, 2000, No 10, 2126-2134.
24. Graffunder, E. M. et R. A. Venezia. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. - J. Antimicrob. Chemother., 49, 2002, 999-1005.
25. Hayden, M. K. Insights into the epidemiology and control of infection with vancomycin-resistant enterococci. - Clin. Infect. Dis., 31, 2000, 31, 1058-1065.
26. Hughes, W. et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. - Clin. Infect. Dis., 34, 2002, 730-751.
27. John, Jr. J. F. et L. B. Rice. The microbial genetics of antibiotic cycling. - Infect. Control Hosp. Epidemiol., 21, 2000, Suppl. S22-S31.
28. Kannangara, S. Management of febrile neutropenia. - Community Oncol., 3, 2006, 585-591.
29. Klastersky, J. et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. - J. Clin. Oncol., 18, 2000, 3038-3051.
30. Kromery, V. Jr. et al. Antibiotic use and development of resistance in blood culture isolates: 8 years of experience from a cancer referral Center. - J. Chemother., 13, 2001, 133-142.
31. Kroschinsky, F. et al. Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation. - Transpl. Infect. Dis., 4, 2002, No 3, 132-136.
32. Krüger, W. et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. - Ann. Oncol., 16, 2005, No 8, 1381-1390.
33. Krüger, W. H. et al. Practices of infectious disease prevention and management during hematopoietic stem cell transplantation: a survey from the European Group for blood and marrow transplantation. - J. Hematother. Stem Cell. Res., 10, 2001, 895-903.
34. Lautenbach, E. et al. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. - Clin. Infect. Dis., 33, 2001, 1288-1294.
35. Lew, M. A. et al. Ciprofloxacine versus trimethoprim-sulfa-methoxasole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. - J. Clin. Oncol., 13, 1995, 239-250.
36. Masterson, R. G. Antibiotic cycling: more than it might seem. - J. Antimicrob. Chemother., 55, 2005, 1-5.
37. Micozzi, A. et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. - Clin. Infect. Dis., 31, 2000, 705-711.
38. Ninin, E. et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. - Clin. Infect. Dis., 33, 2001, 41-47.
39. Nouér, S. A. et al. Risk factors for nosocomial carbapenem-resistant Pseudomonas aeruginosa. Abstract. 12nd Annual Meeting of the Society for Healthcare Epidemiology of America 2002. Salt Lake City, UT, April 6-9, 2002.
40. Nucci, M. Resistant bacteria in stem cell transplant recipients. - Rev. Bras. Hematol. Hemoter., 24, 2002, No 3.
41. Paul, M. et al. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. - J. Antimicrob. Chemother., 57, 2006, No 2, 176-189.
42. Prevention and Treatment of Cancer-Related Infections, NCCN Clinical Practice Guidelines in Oncology. V.1.2007. - www.nccn.org.
43. Ramphal, R. et al. Clinical experience with single agent and combination regimens in management of infection in the febrile neutropenic patient. - Am. J. Med., 100, 1996, 83S-89S.
44. Reuter, S. et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancy. - Clin. Infect. Dis., 40, 2005, 1087-1093.
45. Rovitra, M. et E. Carreras. Infections in HSCT. ESH-EBMT training course on blood and marrow transplantation. Alicante, April 2007.
46. Schimpff, S. et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. - N. Engl. J. Med., 284, 1971, 1061-1065.
47. Sepkowitz, K. A. Antibiotic prophylaxis in patients receiving hematopoietic stem cell transplant. - Bone Marrow Transplant., 29, 2002, 367-371.
48. Shlaes, D. M. et al. Society for Healthcare Epidemiology of America and Infectious Disease Society of America Joint Committee on the Prevention of Antimicrobial Resistance; guidelines for the prevention of antimicrobial resistance in hospitals. - Infect. Control. Hosp. Epidemiol., 18, 1997, 275-291.
49. Sullivan, K. M. et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and Beyond. - Hematology (Am. Soc. Hematol. Educ. Program), 1, 2001, 392-421.
50. Trifilio, S. A. Verma et J. Mehta. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. - Bone Marrow Transplant., 33, 2004, 735-739.
51. World Health Organization. Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs. WHO: Oslo, Norway, 2004. - Available at: http://www.whocc.no/atcdd. Accessed 24 January 2007.
52. Yoshida, M. et R. Ohno. Antimicrobial prophylaxis in febrile neutropenia. - Antimicrob. Prophyl. Clin. Inf. Dis., 39 2004, S65-67.